S 120083
Alternative Names: S-120083; V 120083Latest Information Update: 28 Sep 2023
Price :
$50 *
At a glance
- Originator Purdue Pharma; Shionogi
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Inflammatory pain
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Inflammatory-pain in Japan (PO, Capsule)
- 02 Aug 2021 S 120083 is still in phase I trial in Inflammatory-pain in Japan (PO, Capsule) (Shionogi pipeline, August 2021)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Inflammatory-pain in Japan (PO, Capsule)